EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

The Efficacy and Safety of Tumor Necrosis Factor Alpha Inhibitors in the Treatment of Noninfectious Uveitis: A Systematic Review and Meta-Analysis

Ziyi Wang, Guangyao Li iD, Hai Lu, Jiawei Wang

Journal of Ocular Pharmacology and Therapeutics · 2025

DOI: 10.1177/10807683251363436 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Ocular Pharmacology and Therapeutics, 2025. Verfasst von Ziyi Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Uveitis, Tumor Necrosis Factor-alpha, Tumor Necrosis Factor Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study assessed the comparative efficacy and safety of tumor necrosis factor alpha (TNF-α) inhibitors in treating noninfectious uveitis (NIU).

Methods

A comprehensive search was performed in PubMed, Embase, Cochrane Library, ClinicalTrials.gov, China National Knowledge Infrastructure, and Wanfang Database from January 2010 to March 2024. The outcomes measured included inflammation improvement, visual acuity (VA) improvement, corticosteroid (CS)-sparing effect, central macular thickness (CMT) reduction, and adverse event incidence. Meta-analyses were conducted using RevMan 5.4 and Stata 16 software.

Results

A total of 40 studies were included, involving 3,250 patients. TNF-α inhibitors showed a 90.4% inflammation improvement rate [95% confidence interval (CI): 0.770–0.987], 35.2% VA improvement (95% CI: 0.152–0.553), 55.3% CS-sparing effect (95% CI: 0.297–0.796), and CMT reduction of 62.37 µm (95% CI: 45.41–79.32 µm). Adverse events occurred in 24.0% of patients (95% CI: 0.170–0.310). No significant differences were observed between adalimumab and infliximab in inflammation improvement ( P = 0.60) or CMT reduction ( P = 0.55), but infliximab had higher adverse event rates ( P = 0.0001; relative risk = 1.71, 95% CI: 1.30–2.24).

Conclusions

This meta-analysis demonstrates that TNF-α inhibitors significantly improve inflammation, VA, and reduce CMT and CS use in NIU. While adalimumab and infliximab exhibit comparable efficacy, infliximab is associated with a higher adverse event rate, highlighting the need for personalized treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UveitisTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsHumansVisual AcuityInfliximabAdalimumabTreatment Outcome

Stichwörter der Autor:innen

TNF-α inhibitorsadalimumabetanerceptgolimumabinfliximabnoninfectious uveitis

Substanzen

Tumor Necrosis Factor-alphaInfliximabAdalimumabTumor Necrosis Factor Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
  • Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing Tongren Hospital, Capital Medical University, Beijing, China.

ORCID-Profile: Guangyao Li

Zitieren

APA

Wang, Z., Li, G., Lu, H., & Wang, J. (2025). The Efficacy and Safety of Tumor Necrosis Factor Alpha Inhibitors in the Treatment of Noninfectious Uveitis: A Systematic Review and Meta-Analysis. Journal of Ocular Pharmacology and Therapeutics. https://doi.org/10.1177/10807683251363436

Vancouver

Wang Z, Li G, Lu H, Wang J. The Efficacy and Safety of Tumor Necrosis Factor Alpha Inhibitors in the Treatment of Noninfectious Uveitis: A Systematic Review and Meta-Analysis. Journal of Ocular Pharmacology and Therapeutics. 2025. doi:10.1177/10807683251363436

BibTeX
@article{Wang2025,
  author = {Wang, Ziyi and Li, Guangyao and Lu, Hai and Wang, Jiawei},
  title = {The Efficacy and Safety of Tumor Necrosis Factor Alpha Inhibitors in the Treatment of Noninfectious Uveitis: A Systematic Review and Meta-Analysis},
  journal = {Journal of Ocular Pharmacology and Therapeutics},
  year = {2025},
  doi = {10.1177/10807683251363436}
}
Kostenlos starten →